Sarepta Therapeutics Inc. (NASDAQ:SRPT) shot up 6.7% during trading on Friday . The stock traded as high as $22.39 and last traded at $22.32, with a volume of 2,001,453 shares trading hands. The stock had previously closed at $20.92.

Several research firms have commented on SRPT. JMP Securities restated a “sell” rating and issued a $10.00 target price on shares of Sarepta Therapeutics in a research note on Friday, June 3rd. Vetr upgraded Sarepta Therapeutics from a “strong sell” rating to a “hold” rating and set a $11.60 target price on the stock in a research note on Wednesday, April 27th. Janney Montgomery Scott restated a “hold” rating on shares of Sarepta Therapeutics in a research note on Tuesday, June 7th. Cowen and Company restated a “hold” rating on shares of Sarepta Therapeutics in a research note on Tuesday, June 7th. Finally, Robert W. Baird restated a “buy” rating on shares of Sarepta Therapeutics in a research note on Sunday, May 8th. Five equities research analysts have rated the stock with a sell rating, eight have given a hold rating and seven have issued a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $24.17.

The company’s market capitalization is $1.04 billion. The firm’s 50 day moving average price is $19.11 and its 200-day moving average price is $19.13.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Thursday, May 5th. The company reported ($1.15) EPS for the quarter, topping the Zacks’ consensus estimate of ($1.30) by $0.15. During the same period in the prior year, the business earned ($1.15) EPS. Analysts anticipate that Sarepta Therapeutics Inc. will post ($4.54) earnings per share for the current year.

A number of hedge funds have recently added to or reduced their stakes in the company. Mutual of America Capital Management LLC increased its stake in Sarepta Therapeutics by 0.6% in the fourth quarter. Mutual of America Capital Management LLC now owns 60,108 shares of the company’s stock worth $2,319,000 after buying an additional 358 shares in the last quarter. Nationwide Fund Advisors increased its stake in Sarepta Therapeutics by 9.2% in the fourth quarter. Nationwide Fund Advisors now owns 29,223 shares of the company’s stock worth $1,127,000 after buying an additional 2,471 shares in the last quarter. Swiss National Bank increased its stake in Sarepta Therapeutics by 5.8% in the fourth quarter. Swiss National Bank now owns 61,700 shares of the company’s stock worth $2,380,000 after buying an additional 3,400 shares in the last quarter. New York State Common Retirement Fund increased its stake in Sarepta Therapeutics by 13.5% in the fourth quarter. New York State Common Retirement Fund now owns 44,700 shares of the company’s stock worth $1,725,000 after buying an additional 5,300 shares in the last quarter. Finally, Rhumbline Advisers increased its stake in Sarepta Therapeutics by 16.1% in the fourth quarter. Rhumbline Advisers now owns 47,728 shares of the company’s stock worth $1,841,000 after buying an additional 6,615 shares in the last quarter.

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.